Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
These highlights do not include all the information needed to use EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2018
98342153-b9de-4318-aac4-9f8d19590cd7
HUMAN PRESCRIPTION DRUG LABEL
May 21, 2020
Laurus Labs Limited
DUNS: 915075687
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Product Details
FDA regulatory identification and product classification information